Market Summary
USD151.02-0.03
Market Closed-0.02%
JNJ Alerts
JNJ Stock Price
JNJ RSI Chart
JNJ Valuation
JNJ Price/Sales (Trailing)
JNJ Profitability
JNJ Fundamentals
JNJ Revenue
JNJ Earnings
Price Action
52 Week Range
150.15183.08
(Low)(High)
Last 7 days
-1.9%
Last 30 days
-4.4%
Last 90 days
-14.9%
Trailing 12 Months
-11.7%
JNJ Financial Health
JNJ Investor Care
Peers (Alternatives to Johnson & Johnson)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 396.9B | 94.9B | -4.42% | -11.67% | 22.12 | 4.18 | 1.25% | -14.07% |
LLY | 298.8B | 28.5B | 1.30% | 17.85% | 47.85 | 10.47 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -5.09% | 32.83% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.2B | 100.3B | -5.50% | -20.78% | 7.21 | 2.25 | 23.43% | 42.74% |
BMY | 142.4B | 46.2B | -5.97% | -4.10% | 22.5 | 3.08 | -0.49% | -9.54% |
| MID-CAP | ||||||||
PRGO | 4.5B | 4.5B | -8.55% | -11.11% | -32.05 | 1.01 | 7.56% | -104.06% |
RETA | 3.2B | 2.2M | 109.33% | 133.59% | -10.15 | 1.4K | -80.71% | -4.88% |
| SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -10.48% | 10.28% | 30.48 | 2.77 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -5.76% | -54.20% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -20.83% | -73.20% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 772.8M | 285.2M | -9.04% | -42.36% | 3.51 | 2.71 | -27.21% | -40.28% |
CRON | 726.9M | 114.5M | -12.79% | -47.96% | -4.31 | 6.35 | 27.90% | 57.40% |
ACRS | 539.5M | 29.8M | -36.94% | -53.16% | -6.21 | 18.13 | 340.05% | 4.35% |
OCUL | 379.1M | 51.5M | -14.46% | -5.94% | -5.34 | 7.36 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Financials for Johnson & Johnson
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -1.1% | 94,943 | 96,041 | 95,588 | 94,880 | 93,775 |
| Gross Profit | -1.4% | 63,854 | 64,762 | 64,866 | 64,490 | 63,920 |
| S&GA Expenses | -2.5% | 24,765 | 25,407 | 25,318 | 25,165 | 24,659 |
| EBITDA | -2.0% | 28,971 | 29,560 | 27,685 | 28,604 | - |
| EBITDA Margin | -0.9% | 0.31* | 0.31* | 0.29* | 0.30* | - |
| Earnings Before Taxes | -2.8% | 21,725 | 22,360 | 20,387 | 21,209 | 22,776 |
| EBT Margin | -1.7% | 0.23* | 0.23* | 0.21* | 0.22* | - |
| Interest Expenses | 73.6% | 276 | 159 | 128 | 130 | 183 |
| Net Income | -6.3% | 17,941 | 19,157 | 18,366 | 19,830 | 20,878 |
| Net Income Margin | -5.3% | 0.19* | 0.20* | 0.19* | 0.21* | - |
| Free Cahsflow | -3.1% | 17,185 | 17,739 | 19,950 | 19,733 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 7.0% | 187,378 | 175,124 | 177,724 | 178,355 | 182,018 |
| Current Assets | -15.2% | 55,294 | 65,236 | 63,847 | 60,424 | 60,979 |
| Cash Equivalents | 24.4% | 14,127 | 11,355 | 10,983 | 10,463 | 14,487 |
| Inventory | 6.9% | 12,483 | 11,675 | 11,437 | 10,990 | 10,387 |
| Net PPE | 9.1% | 19,803 | 18,152 | 18,354 | 18,701 | 18,962 |
| Goodwill | 35.5% | 45,231 | 33,383 | 34,166 | 34,935 | 35,246 |
| Liabilities | 10.0% | 110,574 | 100,525 | 101,367 | 103,646 | 107,995 |
| Current Liabilities | 22.5% | 55,802 | 45,543 | 44,821 | 43,390 | 45,226 |
| . Short Term Borrowings | 188.7% | 12,771 | 4,424 | 4,305 | 4,297 | 3,766 |
| Long Term Debt | - | 32,116 | - | - | - | - |
| LT Debt, Current | - | 2,131 | - | - | - | - |
| LT Debt, Non Current | -2.6% | 26,888 | 27,603 | 28,292 | 28,851 | 29,985 |
| Shareholder's Equity | 3.0% | 76,804 | 74,599 | 76,357 | 74,709 | 74,023 |
| Retained Earnings | 0.3% | 128,345 | 127,917 | 126,216 | 124,380 | 123,060 |
| Accumulated Depreciation | -0.9% | 28,529 | 28,790 | 29,001 | 28,717 | - |
| Shares Outstanding | -0.1% | 2,628 | 2,630 | 2,629 | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -1.8% | 21,194 | 21,576 | 23,582 | 23,315 | 23,410 |
| Share Based Compensation | -0.2% | 1,138 | 1,140 | 1,118 | 1,106 | 1,135 |
| Cashflow From Investing | 7.2% | -12,371 | -13,334 | -14,352 | -12,132 | -8,683 |
| Cashflow From Financing | 36.7% | -8,871 | -14,007 | -12,289 | -13,307 | -14,047 |
| Buy Backs | 5.7% | 6,035 | 5,711 | 3,937 | 3,595 | 3,456 |
Risks for JNJ
What is the probability of a big loss on JNJ?
17.7%
Probability that Johnson & Johnson stock will be more than 20% underwater in next one year
0%
Probability that Johnson & Johnson stock will be more than 30% underwater in next one year.
0%
Probability that Johnson & Johnson stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does JNJ drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Johnson & Johnson was unfortunately bought at previous high price.
Drawdowns
Returns for JNJ
Cumulative Returns on JNJ
9.5%
10-Year Cumulative Returns
7.6%
7-Year Cumulative Returns
6.5%
5-Year Cumulative Returns
13.4%
3-Year Cumulative Returns
What are the long-term rolling returns for JNJ?
FIve years rolling returns for Johnson & Johnson.
Annualized Returns
Which funds bought or sold JNJ recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 3.92 | 3,092,040 | 29,398,000 | 0.82% |
2023-03-14 | AWM CAPITAL, LLC | added | 4.65 | 19,854 | 492,854 | 0.17% |
2023-03-13 | Claro Advisors LLC | added | 11.7 | 325,670 | 3,244,670 | 1.06% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 9.09 | 3,078 | 19,078 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -3.08 | 23,020,400 | 502,397,000 | 0.55% |
2023-03-10 | MATHER GROUP, LLC. | added | 4.4 | 543,679 | 4,761,680 | 0.09% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | added | 0.04 | 178,338 | 2,361,340 | 0.37% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 3.73 | 413,385 | 3,381,380 | 0.27% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 1,239,020 | 1,239,020 | 0.32% |
2023-03-07 | Nordwand Advisors, LLC | new | - | 188,939,000 | 188,939,000 | 23.56% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
JNJ Alerts
Johnson & Johnson News
Schedule 13G FIlings of Johnson & Johnson
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.44% | 246,826,621 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.6% | 198,802,769 | SC 13G/A | |
| Feb 14, 2022 | state street corp | 5.51% | 144,996,127 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 8.92% | 234,782,632 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.6% | 200,021,352 | SC 13G/A | |
| Feb 12, 2021 | state street corp | 5.47% | 144,029,634 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 8.66% | 227,946,104 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.2% | 188,510,542 | SC 13G/A | |
| Feb 13, 2020 | state street corp | 5.77% | 151,867,233 | SC 13G | |
| Feb 12, 2020 | vanguard group inc | 8.67% | 228,297,775 | SC 13G/A |
JNJ Fair Value
Johnson & Johnson fair value in different scenarios
The table shows the Fair Value estimates for Johnson & Johnson for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 71.21 -52.85% | 93.65 -37.99% | 134.05 -11.24% | 169.21 12.04% | 199.06 31.81% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Johnson & Johnson Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Johnson & Johnson
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 22, 2023 | PX14A6G | PX14A6G | |
| Mar 16, 2023 | ARS | ARS | |
| Mar 15, 2023 | DEF 14A | DEF 14A | |
| Mar 15, 2023 | DEFA14A | DEFA14A | |
| Mar 15, 2023 | DEFA14A | DEFA14A | |
| Mar 09, 2023 | 4 | Insider Trading | |
| Mar 09, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 3 | Insider Trading | |
| Feb 16, 2023 | 10-K | Annual Report |
Latest Insider Trading transactions for JNJ
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-06 | Swanson James D. | sold | -164,199 | 154 | -1,061 | see remarks |
2023-02-13 | Wengel Kathryn E | acquired | - | - | 10,839 | evp, chief to and risk officer |
2023-02-13 | Mongon Thibaut | acquired | - | - | 13,710 | exec vp, ww chair, cons health |
2023-02-13 | Duato Joaquin | sold (taxes) | -2,203,170 | 162 | -13,599 | ceo and chairman of the board |
2023-02-13 | Fasolo Peter | acquired | - | - | 12,468 | exec vp, chief hr officer |
2023-02-13 | Hait William | acquired | - | - | 9,640 | see remarks |
2023-02-13 | Hait William | sold (taxes) | -742,978 | 162 | -4,586 | see remarks |
2023-02-13 | Forminard Elizabeth | acquired | - | - | 2,555 | executive vp, general counsel |
2023-02-13 | Wolk Joseph J | sold (taxes) | -1,389,720 | 162 | -8,578 | exec vp, cfo |
2023-02-13 | Broadhurst Vanessa | acquired | - | - | 3,981 | evp, global corp affairs |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
JNJ Income Statement
2023-01-01Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Jan. 01, 2023 | Jan. 02, 2022 | Jan. 03, 2021 | |
| Income Statement [Abstract] | |||
| Sales to customers | $ 94,943 | $ 93,775 | $ 82,584 |
| Cost of products sold | 31,089 | 29,855 | 28,427 |
| Gross profit | 63,854 | 63,920 | 54,157 |
| Selling, marketing and administrative expenses | 24,765 | 24,659 | 22,084 |
| Research and development expense | 14,603 | 14,714 | 12,159 |
| In-process research and development (Note 5) | 783 | 900 | 181 |
| Interest income | (490) | (53) | (111) |
| Interest expense, net of portion capitalized (Note 4) | 276 | 183 | 201 |
| Other (income) expense, net | 1,871 | 489 | 2,899 |
| Restructuring (Note 20) | 321 | 252 | 247 |
| Earnings before provision for taxes on income | 21,725 | 22,776 | 16,497 |
| Provision for taxes on income (Note 8) | 3,784 | 1,898 | 1,783 |
| Net earnings | $ 17,941 | $ 20,878 | $ 14,714 |
| Net earnings per share (Notes 1 and 15) | |||
| Basic (in dollars per share) | $ 6.83 | $ 7.93 | $ 5.59 |
| Diluted (in dollars per share) | $ 6.73 | $ 7.81 | $ 5.51 |
| Average shares outstanding (Notes 1 and 15) | |||
| Basic (in shares) | 2,625.2 | 2,632.1 | 2,632.8 |
| Diluted (in shares) | 2,663.9 | 2,674.0 | 2,670.7 |
JNJ Balance Sheet
2023-01-01Consolidated Balance Sheets - USD ($) $ in Millions | Jan. 01, 2023 | Jan. 02, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents (Notes 1 and 2) | $ 14,127 | $ 14,487 |
| Marketable securities (Notes 1 and 2) | 9,392 | 17,121 |
| Accounts receivable trade, less allowances for doubtful accounts $203 (2021, $230) | 16,160 | 15,283 |
| Inventories (Notes 1 and 3) | 12,483 | 10,387 |
| Prepaid expenses and other receivables | 3,132 | 3,701 |
| Total current assets | 55,294 | 60,979 |
| Property, plant and equipment, net (Notes 1 and 4) | 19,803 | 18,962 |
| Intangible assets, net (Notes 1 and 5) | 48,325 | 46,392 |
| Goodwill (Notes 1 and 5) | 45,231 | 35,246 |
| Deferred taxes on income (Note 8) | 9,123 | 10,223 |
| Other assets | 9,602 | 10,216 |
| Total assets | 187,378 | 182,018 |
| Current liabilities | ||
| Loans and notes payable (Note 7) | 12,771 | 3,766 |
| Accounts payable | 11,703 | 11,055 |
| Accrued liabilities | 11,456 | 13,612 |
| Accrued rebates, returns and promotions | 14,417 | 12,095 |
| Accrued compensation and employee related obligations | 3,328 | 3,586 |
| Accrued taxes on income (Note 8) | 2,127 | 1,112 |
| Total current liabilities | 55,802 | 45,226 |
| Long-term debt (Note 7) | 26,888 | 29,985 |
| Deferred taxes on income (Note 8) | 6,374 | 7,487 |
| Employee related obligations (Notes 9 and 10) | 6,767 | 8,898 |
| Long-term taxes payable (Note 1) | 4,306 | 5,713 |
| Other liabilities | 10,437 | 10,686 |
| Total liabilities | 110,574 | 107,995 |
| Commitments and Contingencies (Note 19) | ||
| Shareholders’ equity | ||
| Preferred stock — without par value (authorized and unissued 2,000,000 shares) | 0 | 0 |
| Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
| Accumulated other comprehensive income (loss) (Note 13) | (12,967) | (13,058) |
| Retained earnings | 128,345 | 123,060 |
| Stockholders' Equity before Treasury Stock | 118,498 | 113,122 |
| Less: common stock held in treasury, at cost (Note 12) (506,246,000 shares and 490,878,000 shares) | 41,694 | 39,099 |
| Total shareholders’ equity | 76,804 | 74,023 |
| Total liabilities and shareholders’ equity | $ 187,378 | $ 182,018 |